Analyst ratings, especially from reputable firms like Guggenheim, can significantly influence investor sentiment and stock prices. The downgrade from a Buy to Neutral suggests a less optimistic outlook on Altimmune's stock, likely leading to decreased investor confidence and a short-term decline in stock price.